1032903-64-2

Usage

Uses

Used in Pharmaceutical Research and Development:
4-[4-[[5-Chloro-4-[[2-[(propan-2-yl)sulfonyl]phenyl]amino]pyrimidin-2-yl]amino]-5-isopropoxy-2-methylphenyl]piperidine-1-carboxylic acid tert-butyl ester is used as a research compound for exploring its potential pharmaceutical applications. Its unique structural features, including the presence of a piperidine core and various functional groups, make it a promising candidate for the development of new drug candidates.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-[4-[[5-Chloro-4-[[2-[(propan-2-yl)sulfonyl]phenyl]amino]pyrimidin-2-yl]amino]-5-isopropoxy-2-methylphenyl]piperidine-1-carboxylic acid tert-butyl ester is utilized for studying its interactions with biological targets and understanding its mechanism of action. This knowledge can contribute to the design and optimization of more effective and selective drug molecules.
Used in Drug Synthesis:
4-[4-[[5-Chloro-4-[[2-[(propan-2-yl)sulfonyl]phenyl]amino]pyrimidin-2-yl]amino]-5-isopropoxy-2-methylphenyl]piperidine-1-carboxylic acid tert-butyl ester can be employed as a key intermediate in the synthesis of more complex drug molecules. Its versatile functional groups allow for further chemical modifications and the development of novel therapeutic agents.
Used in Biochemical Assays and Screening:
In biochemical assays and high-throughput screening processes, 4-[4-[[5-Chloro-4-[[2-[(propan-2-yl)sulfonyl]phenyl]amino]pyrimidin-2-yl]amino]-5-isopropoxy-2-methylphenyl]piperidine-1-carboxylic acid tert-butyl ester serves as a test compound to evaluate its biological activity and selectivity towards specific targets. This information is crucial for assessing its potential as a lead compound in drug discovery programs.
Used in Drug Delivery Systems:
4-[4-[[5-Chloro-4-[[2-[(propan-2-yl)sulfonyl]phenyl]amino]pyrimidin-2-yl]amino]-5-isopropoxy-2-methylphenyl]piperidine-1-carboxylic acid tert-butyl ester may be incorporated into drug delivery systems to improve the pharmacokinetic and pharmacodynamic properties of the resulting drug formulations. Its functional groups can be exploited for conjugation to various carriers, enhancing the drug's bioavailability, stability, and targeted delivery to specific tissues or cells.

Upstream product

• 761440-16-8 2-chloro-N-(2-(isopropylsulfonyl)phenyl)-5-methyl-pyrimidin-4-amine 
• 1032903-63-1 4-(4-amino-5-isopropoxy-2-methylphenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 76697-50-2 1-amino-2-(isopropylsulphonyl)benzene 
• 70415-86-0 1-(isopropylsulfonyl)-2-nitrobenzene 
• 70415-85-9 2-(isopropyl sulfanyl)nitrobenzene 
• 1493-27-2 ortho-nitrofluorobenzene 
• 1202858-68-1 1-bromo-5-isopropoxy-2-methyl-4-nitrobenzene 
• 1254062-68-4 2-bromo-4-isopropoxy-1-methylbenzene 
• 60710-39-6 3-bromo-p-cresol 
• 1032903-52-8 4-(2-methyl-4-nitro-5-isopropoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 1035230-24-0 5-chloro-N²-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N⁴-((2-isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine 
• 452-73-3 2-chloro-4-fluorotoluene 
• 1032903-62-0 4-[2-methyl-4-nitro-5-(propan-2-yloxy)phenyl]pyridine 

Downstream Products

• 1380575-43-8 ceritinib hydrochloride 
• 1380575-43-8 5-chloro-N²-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N⁴-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine hydrochloride 
• 1445895-03-3 5-chloro-N₂-(2-isopropoxy-5-methyl-4-(1-ethylpiperidin-4-yl)phenyl)-N₄-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine 
• 1445895-04-4 5-chloro-N₂-(2-isopropoxy-5-methyl-4-(1-isopropylpiperidin-4-yl)phenyl)-N₄-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine 
• 1445895-08-8 5-chloro-N₂-(4-(1-(2,2-difluoroethyl)piperidin-4-yl)-2-isopropoxy-5-methylphenyl)-N₄-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine 
• 1190399-47-3 1-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-2-(dimethylamino)ethanone 
• 1032900-25-6 5-chloro-N²-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-N⁴-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine 

Relevant academic research and scientific papers

Preparation method of ceritinib and key intermediate thereof

The invention discloses a preparation method of ceritinib and a key intermediate thereof and belongs to the field of medicinal chemistry. The purity of a final product is high and reaches 99.7 percentand the yield is high and reaches 92.7 percent; the preparation method is simple to operate and column chromatography is not needed; furthermore, first-step reaction selectively acts on specific chlorine atoms on pyrimidine and NH in a compound 2 is protected so that side effects are few, requirements on reaction conditions are relatively low, the yield is high, the purity is high and the post-treatment is simple; industrial production is easy to realize.

A method for preparing color Switzerland for Nepal

The invention discloses a method for preparing ceritinib, belonging to the field of chemical pharmacy. The method comprises the following steps: by taking 3-bromine-4-methylphenol as an initial raw material, performing phenolic hydroxyl isopropylation, nitration, coupling and reduction reaction, obtaining a midbody 1, by further taking o-nitro fluorobenzene as another initial raw material, performing isosulfhydrylation, oxidation, reduction and pyrimidine, obtaining a midbody 2, performing coupling reduction on the midbody 1 and the midbody 1, obtaining ceritinib which is protected by BOC acid anhydride, and finally removing a t-butyloxycarboryl protecting group, and obtaining ceritinib. The method is simple and feasible to operate, relatively high in yield, small in pollution and applicable to industrial production.

Method for preparing ALK inhibitor ceritinib

Embodiment of present disclosure provides a method for preparing ceritinib of formula I, comprising: (1) contacting a compound of formula 12b with an amino protective group to obtain a compound of formula 3; (2) contacting the compound of formula 3 with a compound of formula 9a to obtain a compound of formula 5; and (3) subjecting the compound of formula 5 to a deprotection reaction to obtain the ceritinib of formula I. Then ceritinib may be effectively prepared.

Novel kinase inhibitors

The present invention relates to a novel kinase inhibitor useful as a medicine for tumor, nerve disorder and mental illness. The purpose of the present invention is to provide a compound having improved blood-aqueous barrier penetrability to neurodegenerative diseases that cancer spreads to brain or progresses in brain. To this end, provided is a compound represented by chemical formula 1 or a pharmaceutically allowable salt thereof.COPYRIGHT KIPO 2017

Preparation method for ALK inhibitor

The invention provides a preparation method for an ALK inhibitor. The preparation method comprises a step of contacting a compound as shown in a formula 4 with a compound as shown in a formula 12. The method can rapidly and efficiently prepare the target ALK inhibitor and is simple in steps, mild in reaction conditions and low in cost.

Synthesis and anticancer activities of ceritinib analogs modified in the terminal piperidine ring

A series of new ceritinib analogs by extensive functionalization of the tail piperidine ring with various phosphamides and carbamates have been synthesized. All the ceritinib derivatives were evaluated for their cytotoxic activities against H2228 cell line. From the activity profile obtained, three of the tested compounds (compounds 4, 7 and 9) showed significant cytotoxic effects. Among these derivatives compound 9 was found to possess cytotoxicity that is better than standard drug ceritinib (IC50 Combining double low line 24 nM). Moreover, compound 9 demonstrated robust tumor growth inhibition in vivo model.

Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro- N 2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)- N 4-(2-(isopropylsulfonyl) phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials

The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are described. In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684). Compound 15b is currently in phase 1 and phase 2 clinical trials with substantial antitumor activity being observed in ALK-positive cancer patients.

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.